OrbiMed β 2015 Investments
9 investments dated 2015 Β· listed companies and verified rows first Β· show all
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)
BoardFlorent Gros(Director)Erez Chimovits(Director)in
Board seatJonathan SilversteinCarl GordonΒ· per SEC Form D
Co-investorsForesite CapitalPontifax Venture CapitalQuan CapitalaMoonNovartis Venture Fund
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)Manuel Litchman(Executive Officer, Director)
BoardLiam Ratcliffe(Director)inTim Shannon(Director)inKush Parmar(Director)
Board seatStephen SquintoΒ· per SEC Form D Β· $55M raise Β· filed Apr 2018
Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsNextech InvestRA Capital+1 more
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)
Board seatChau KhuongΒ· per SEC Form D Β· $93.4M raise Β· filed Nov 2018
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+2 more
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)
BoardSteve Squinto(Director)inKush Parmar(Director)Jonathan Leff(Director)Thomas Woiwode(Director)
Board seatJonathan SilversteinΒ· per SEC Form D Β· filed Sep 2015
Co-investorsAsset Management CompanyRA CapitalvenBio PartnersDeerfield Management CompanyVenrock
Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.
BiotechHealthtechMedical DevicesWestminster, US
Andrew J Tofe(Director)Britt Pearson(Executive Officer)Jeff Marx(Executive Officer)Glen Kashuba(Executive Officer, Director)Jerome Connor(Executive Officer)Andrew Handwerker(Executive Officer)
Board seatChau KhuongJonathan SilversteinΒ· per SEC Form D Β· $4M raise Β· filed Feb 2015
BiotechDorval
Francois Nader(Director)Donna Roy Grogan(Executive Officer)Jean-Francois Pariseau(Executive Officer, Director)Michael Singer(Executive Officer)David P. Bonita(Director)inRobert Heft(Director)
Board seatDavid BonitaΒ· per SEC Form D Β· $60M raise Β· filed Jul 2015
BiotechBurlingame, US
John Celebi(Executive Officer)Mary Haak-Frendscho(Executive Officer, Director)
BoardJohn Diekman(Director)inDavid Goeddel(Director)Robert Schreiber(Director)
Board seatCarl GordonΒ· per SEC Form D Β· $6.3M raise Β· filed Jan 2015
Co-investors5AM VenturesThe Column Group
Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.
BiotechHealthtechBoston, US
Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)
BoardEdward T. Mathers(Director)inNeil Exter(Director)inTodd Foley(Director)
Board seatJonathan SilversteinΒ· per SEC Form D Β· $40M raise Β· filed Dec 2015
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsThird Rock Ventures
Cambridge, US
Annalisa Jenkins(Executive Officer, Director)
BoardBenjamin Auspitz(Director)Donald J. Hayden(Director)Allan Fox(Director)
Co-investorsF-Prime CapitalNew Leaf Venture Partners
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.